Zhitong Finance App News, Huaren Pharmaceutical (300110.SZ) issued an announcement. Recently, Anhui Hengxing Pharmaceutical Co., Ltd. (hereinafter referred to as “Anhui Hengxing Pharmaceutical”), a wholly-owned subsidiary of the company, received the approval and issuance of “Bumetanil” and “Notice of Approval of the Marketing Application for Chemical Ingredients” (Notice Number: 2025YS00519) from the China Drug Administration.

Zhitongcaijing · 07/02 09:09
Zhitong Finance App News, Huaren Pharmaceutical (300110.SZ) issued an announcement. Recently, Anhui Hengxing Pharmaceutical Co., Ltd. (hereinafter referred to as “Anhui Hengxing Pharmaceutical”), a wholly-owned subsidiary of the company, received the approval and issuance of “Bumetanil” and “Notice of Approval of the Marketing Application for Chemical Ingredients” (Notice Number: 2025YS00519) from the China Drug Administration.